- Home
- ALX vs PRCT Comparison
ALX vs PRCT Comparison
Compare ALX & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | PRCT |
|---|---|---|
| Founded | 1928 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALX | PRCT |
|---|---|---|
| Price | $250.06 | $25.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $35.44 |
| AVG Volume (30 Days) | 27.6K | ★ 1.1M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 7.24% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ 5.50 | N/A |
| Revenue | $213,183,000.00 | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | N/A | $24.52 |
| P/E Ratio | $45.21 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $198.57 | $19.35 |
| 52 Week High | $260.84 | $64.89 |
Technical Indicators
Market Signals| Indicator | ALX | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 49.85 |
| Support Level | $228.61 | $22.81 |
| Resistance Level | $248.67 | $28.57 |
| Average True Range (ATR) | 6.22 | 1.18 |
| MACD | 1.26 | 0.21 |
| Stochastic Oscillator | 81.83 | 70.90 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.